CoChat

Liver–Heart on chip models for drug safety

Open access
Ferrari, Erika, Rasponi, Marco · 2021 · APL Bioengineering

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Abstract

Current pre-clinical models to evaluate drug safety during the drug development process (DDP) mainly rely on traditional two-dimensional cell cultures, considered too simplistic and often ineffective, or animal experimentations, which are costly, time-consuming, and not truly representative of human responses. Their clinical translation thus remains limited, eventually causing attrition and leading to high rates of failure during clinical trials. These drawbacks can be overcome by the recently developed Organs-on-Chip (OoC) technology. OoC are sophisticated in vitro systems capable of recapitulating pivotal architecture and functionalities of human organs. OoC are receiving increasing attention from the stakeholders of the DDP, particularly concerning drug screening and safety applications. When a drug is administered in the human body, it is metabolized by the liver and the resulting compound may cause unpredicted toxicity on off-target organs such as the heart. In this sense, several liver and heart models have been widely adopted to assess the toxicity of new or recalled drugs. Recent advances in OoC technology are making available platforms encompassing multiple organs fluidically connected to efficiently assess and predict the systemic effects of compounds. Such Multi-Organs-on-Chip (MOoC) platforms represent a disruptive solution to study drug-related effects, which results particularly useful to predict liver metabolism on off-target organs to ultimately improve drug safety testing in the pre-clinical phases of the DDP. In this review, we focus on recently developed liver and heart on chip systems for drug toxicity testing. In addition, MOoC platforms encompassing connected liver and heart tissues have been further reviewed and discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1063/5.0048986

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. (a) 3D schematic representation of the phaseguide-based microfluidic device encompassing HepG2 cells embedded in ECM separated from fluid flow by the phaseguides (i); (ii) albumin and urea production within 18 days under 2D, 3D, and chip conditions: data are shown as mean ± SD (n = 3); (iii) phase-contrast images of HepG2 cells cultured in the perfused chip and exposed to increasing concentrations (0.5, 5, 25 mM) of APAP. Reproduced with the permission from Jang et al., Biomicrofluidics 9, 1–12 (2015). Copyright 2015 AIP Publishing.43 (b) Concept of the tissue incubator (i) and the schematic of the radial flow generated (ii); (iii) radial gradient and dose‐associated zonal hepatotoxicity within the device: (a)–(d) radial gradient, (e) relative APAP‐induced hepatotoxicity at day 0 and day 7 standard Petri dish, (f) and (g) recapitulation of APAP‐induced hepatotoxicity (1200 mg/l APAP) at day 7 within the device compared to day 1 (h) and (i). The yellow arrow shows the direction of the flow. Reproduced with permission from Weng et al., Adv. Mater. 29, 1–7 (2017). Copyright 2017 John Wiley and Sons.45 (c) Picture of assembled device and real image of HepG2/C3A organoid after overnight incubation (i); the graphs show Oxygen Consumption Rates (OCR) measured on isolated mitochondria for 30 min, followed by a first Adenosine diphosphate (ADP) injection (arrow) and a second injection of 50 μM rotenone (ii) or troglitazone (iii). **P <0.01 by student's t test. Reproduced with permission from Bavli et al., Proc. Natl. Acad. Sci. 113(16), E2231–E2240 (2016). Copyright 2016 PNAS.47 (d) Concept of dynamic co-culture (i) optimal condition with hepatocytes (red) and liver sinusoidal endothelial cells (LSEC, yellow) and dynamic monoculture (ii); (iii) albumin production after 3 days of culture in both conditions using the Exoliver (ExL). N = 4 independent experiments and expressed as mean ± standard error of the mean. *p value <0.05 vs conventional culture; (iv) ExL‐cultured hepatocytes reaction to acute DILI (24 h with 100 μM troglitazone and 100 μM tolcapone): hepatocytes viability, urea and albumin synthesis, transaminases (ALT: alanine aminotransferase, AST: aspartate aminotransferase), and lactate dehydrogenase (LDH) production. N = 4 independent experiments expressed as mean ± standard error of the mean. *p value <0.05 vs its corresponding vehicle. Reproduced with permission from Ortega-Ribera et al., Biotechnol. Bioeng. 115(10), 2585–2594 (2018). Copyright 2018 Authors, licensed under a Creative Commons Attribution (CC BY) license.54 (e) Concept of liver sinusoid structure within the device (i); (ii) comparison between the 96-well plate HepG2 model and LoC device of drug interactions: hepatotoxicity (LDH levels) of 20 mM APAP in combination with 50 μM RIF, 50 μM OME, and 25 μM CPFX. N = 3 experimental models. Reproduced with the permission from Deng et al. Biomicrofluidics. 13(2), 024101 (2019). Copyright 2019 AIP Publishing.57
FIG. 1. (a) 3D schematic representation of the phaseguide-based microfluidic device encompassing HepG2 cells embedded in ECM separated from fluid flow by the phaseguides (i); (ii) albumin and urea production within 18 days under 2D, 3D, and chip conditions: data are shown as mean ± SD (n = 3); (iii) phase-contrast images of HepG2 cells cultured in the perfused chip and exposed to increasing concentrations (0.5, 5, 25 mM) of APAP. Reproduced with the permission from Jang et al., Biomicrofluidics 9, 1–12 (2015). Copyright 2015 AIP Publishing.43 (b) Concept of the tissue incubator (i) and the schematic of the radial flow generated (ii); (iii) radial gradient and dose‐associated zonal hepatotoxicity within the device: (a)–(d) radial gradient, (e) relative APAP‐induced hepatotoxicity at day 0 and day 7 standard Petri dish, (f) and (g) recapitulation of APAP‐induced hepatotoxicity (1200 mg/l APAP) at day 7 within the device compared to day 1 (h) and (i). The yellow arrow shows the direction of the flow. Reproduced with permission from Weng et al., Adv. Mater. 29, 1–7 (2017). Copyright 2017 John Wiley and Sons.45 (c) Picture of assembled device and real image of HepG2/C3A organoid after overnight incubation (i); the graphs show Oxygen Consumption Rates (OCR) measured on isolated mitochondria for 30 min, followed by a first Adenosine diphosphate (ADP) injection (arrow) and a second injection of 50 μM rotenone (ii) or troglitazone (iii). **P <0.01 by student's t test. Reproduced with permission from Bavli et al., Proc. Natl. Acad. Sci. 113(16), E2231–E2240 (2016). Copyright 2016 PNAS.47 (d) Concept of dynamic co-culture (i) optimal condition with hepatocytes (red) and liver sinusoidal endothelial cells (LSEC, yellow) and dynamic monoculture (ii); (iii) albumin production after 3 days of culture in both conditions using the Exoliver (ExL). N = 4 independent experiments and expressed as mean ± standard error of the mean. *p value <0.05 vs conventional culture; (iv) ExL‐cultured hepatocytes reaction to acute DILI (24 h with 100 μM troglitazone and 100 μM tolcapone): hepatocytes viability, urea and albumin synthesis, transaminases (ALT: alanine aminotransferase, AST: aspartate aminotransferase), and lactate dehydrogenase (LDH) production. N = 4 independent experiments expressed as mean ± standard error of the mean. *p value <0.05 vs its corresponding vehicle. Reproduced with permission from Ortega-Ribera et al., Biotechnol. Bioeng. 115(10), 2585–2594 (2018). Copyright 2018 Authors, licensed under a Creative Commons Attribution (CC BY) license.54 (e) Concept of liver sinusoid structure within the device (i); (ii) comparison between the 96-well plate HepG2 model and LoC device of drug interactions: hepatotoxicity (LDH levels) of 20 mM APAP in combination with 50 μM RIF, 50 μM OME, and 25 μM CPFX. N = 3 experimental models. Reproduced with the permission from Deng et al. Biomicrofluidics. 13(2), 024101 (2019). Copyright 2019 AIP Publishing.57CC BY · PubMed Central
FIG. 2. (a) (i) Concept and real picture of the device. Scale bar is 1 cm; platform validation with blebbistatin: hiPSC-CMs field potential (measured by the MEA, red) and contraction (measured by the IDE, blue) before drug treatment (ii), and after 10 μM blebbistatin administration (iii). Republished with permission from Qian et al., Lab Chip 17, 1732–1739 (2017). Copyright 2017 Royal Society of Chemistry, Clearance Center, Inc.61 (b) Heart-on-a-chip device fabricated from three PDMS layers, aligned and irreversibly bonded (i) and (ii); real picture of an actual 3D heart-on-chip device (iii); (iv) contraction rate measured within cardiac constructs in response to increasing isoprenaline concentration (10−12–10−6 M) in the presence (+ES, blue) or absence (−ES, red) of electrical stimulation (*p <0.05, ***p <0.0001). Republished with permission from Marsano et al., Lab Chip 16(3), 599–610 (2016). Copyright 2016 Clearance Center, Inc.70 (c) Schematic of the system with engineered Ewing sarcoma (ES) tumor and cardiac tissues (i), cultured either with microfluidic perfusion (integrated) or in isolation; viability of ES tumors and cardiac tissues with and without Linsitinib treatment (12 μM, 72 h) comparing isolated and integrated conditions (ii); beat frequency of cardiac tissues after exposure to Linsitinib (12 μM) (mean ± s.e.m., n = 11) in isolation (iii) and in the integrated platform (iv). Republished with permission of Chramiec et al., Lab Chip 20(23), 4357–4372 (2020). Copyright 2020 Clearance Center, Inc.77 (D) (i) Concept of the Biowire II platform with atrio-ventricular ends; (ii) atrial Green Fluorescent Protein (GFP+) and ventricular (GFP−) CMs are placed at the opposite ends of the system suspended between two POMaC wires. Scale bar = 0.5 mm; (iii) ventricular end of the tissues stained positive for myosin light chain 2v (MLC2v). Scale bar = 0.5 mm; (iv) difference in Ca2+ transient amplitude after serotonin administration, normalized to the baseline (N = 3, two-way ANOVA with Sidak's test); (v) value of the conduction velocity upon ranolazine application after normalization to the baseline (mean ± SD, N = 4, p = 0.0007, student's t test). Reprinted with permission from Zhao et al., Cell 176(4), 913–927 (2019). Copyright 2019 Elsevier.79 (e) (i) Steps of the cell seeding process in the device; (ii) real images of the cardiac tissue modeled around the scaffold from day 0 to day 4. Scale bar, 200 μm; (iii) changes in cantilever displacements during spontaneous contraction of the construct and after epinephrine (10 μM) stimulation; (iv) quantification of the variations in beating frequency and contraction force under epinephrine stimulation. Reproduced with permission from Lai et al., Adv. Funct. Mater. 27, 1–11 (2017). Copyright 2017 John Wiley and Sons.52 (f) (i) Picture of the TEER–MEA chip. Scale bar is 2 cm; (ii) concept of the platform: endothelial monolayer cultured on top of the PET membrane while cardiomyocytes on top of MEAs, and both cell types cultured between the two sets of TEER electrodes. (ii) Isoproterenol directly administered to the cardiomyocyte channel show an increase in both the beat rate by 80% (iii) and the corrected field potential duration (cFPD) by 90% (iv) whereas it did not have effect when administered through the endothelial channel; isoproterenol administered through the damaged endothelial channel (+TNF-α) shows a significant increase in both the beat rate by 28% (iii) and the cFPD by 42% (iv). Republished with permission from Maoz et al., Lab Chip 17, 2294–2302 (2017). Copyright 2017 Copyright Clearance Center, Inc.83 (g) (i) Steps showing the procedure of fabricating the endothelialized myocardium using the 3D bioprinting method; exploded view of the device: two-layer microfluidic bioreactor sandwiched by a pair of polymethylmethacrylate (PMMA) clamps (ii) and real picture of the bioreactor containing a bioprinted scaffold (iii); relative beating (iv) of the endothelialized myocardial tissues and the levels of vWF expression (v) by the endothelial cells after increasing doxorubicin concentration. Reprinted with permission from Zhang et al., Biomaterials 110, 45–59, Copyright 2016 Elsevier.85
FIG. 2. (a) (i) Concept and real picture of the device. Scale bar is 1 cm; platform validation with blebbistatin: hiPSC-CMs field potential (measured by the MEA, red) and contraction (measured by the IDE, blue) before drug treatment (ii), and after 10 μM blebbistatin administration (iii). Republished with permission from Qian et al., Lab Chip 17, 1732–1739 (2017). Copyright 2017 Royal Society of Chemistry, Clearance Center, Inc.61 (b) Heart-on-a-chip device fabricated from three PDMS layers, aligned and irreversibly bonded (i) and (ii); real picture of an actual 3D heart-on-chip device (iii); (iv) contraction rate measured within cardiac constructs in response to increasing isoprenaline concentration (10−12–10−6 M) in the presence (+ES, blue) or absence (−ES, red) of electrical stimulation (*p <0.05, ***p <0.0001). Republished with permission from Marsano et al., Lab Chip 16(3), 599–610 (2016). Copyright 2016 Clearance Center, Inc.70 (c) Schematic of the system with engineered Ewing sarcoma (ES) tumor and cardiac tissues (i), cultured either with microfluidic perfusion (integrated) or in isolation; viability of ES tumors and cardiac tissues with and without Linsitinib treatment (12 μM, 72 h) comparing isolated and integrated conditions (ii); beat frequency of cardiac tissues after exposure to Linsitinib (12 μM) (mean ± s.e.m., n = 11) in isolation (iii) and in the integrated platform (iv). Republished with permission of Chramiec et al., Lab Chip 20(23), 4357–4372 (2020). Copyright 2020 Clearance Center, Inc.77 (D) (i) Concept of the Biowire II platform with atrio-ventricular ends; (ii) atrial Green Fluorescent Protein (GFP+) and ventricular (GFP−) CMs are placed at the opposite ends of the system suspended between two POMaC wires. Scale bar = 0.5 mm; (iii) ventricular end of the tissues stained positive for myosin light chain 2v (MLC2v). Scale bar = 0.5 mm; (iv) difference in Ca2+ transient amplitude after serotonin administration, normalized to the baseline (N = 3, two-way ANOVA with Sidak's test); (v) value of the conduction velocity upon ranolazine application after normalization to the baseline (mean ± SD, N = 4, p = 0.0007, student's t test). Reprinted with permission from Zhao et al., Cell 176(4), 913–927 (2019). Copyright 2019 Elsevier.79 (e) (i) Steps of the cell seeding process in the device; (ii) real images of the cardiac tissue modeled around the scaffold from day 0 to day 4. Scale bar, 200 μm; (iii) changes in cantilever displacements during spontaneous contraction of the construct and after epinephrine (10 μM) stimulation; (iv) quantification of the variations in beating frequency and contraction force under epinephrine stimulation. Reproduced with permission from Lai et al., Adv. Funct. Mater. 27, 1–11 (2017). Copyright 2017 John Wiley and Sons.52 (f) (i) Picture of the TEER–MEA chip. Scale bar is 2 cm; (ii) concept of the platform: endothelial monolayer cultured on top of the PET membrane while cardiomyocytes on top of MEAs, and both cell types cultured between the two sets of TEER electrodes. (ii) Isoproterenol directly administered to the cardiomyocyte channel show an increase in both the beat rate by 80% (iii) and the corrected field potential duration (cFPD) by 90% (iv) whereas it did not have effect when administered through the endothelial channel; isoproterenol administered through the damaged endothelial channel (+TNF-α) shows a significant increase in both the beat rate by 28% (iii) and the cFPD by 42% (iv). Republished with permission from Maoz et al., Lab Chip 17, 2294–2302 (2017). Copyright 2017 Copyright Clearance Center, Inc.83 (g) (i) Steps showing the procedure of fabricating the endothelialized myocardium using the 3D bioprinting method; exploded view of the device: two-layer microfluidic bioreactor sandwiched by a pair of polymethylmethacrylate (PMMA) clamps (ii) and real picture of the bioreactor containing a bioprinted scaffold (iii); relative beating (iv) of the endothelialized myocardial tissues and the levels of vWF expression (v) by the endothelial cells after increasing doxorubicin concentration. Reprinted with permission from Zhang et al., Biomaterials 110, 45–59, Copyright 2016 Elsevier.85CC BY · PubMed Central
FIG. 3. (a) (i) Concept of the modular multitissue chip hardware system setup for culture of three different models connected via a central fluid routing breadboard; (ii) illustration of the two drug, two organoid interactions; (iii) cardiac organoids beating values in response to both 0.1 μM propranolol and 0.5 μM epinephrine with presence and absence of the liver module; (iv) increases in beating from epinephrine addition are blocked by 0.1 μM propranolol in the absence or presence of liver module (both organoids or 2D hepatocytes). 2D hepatocytes metabolism is reduced in comparison to hepatic organoids. Statistical significance: *p <0.05. Reproduced with permission from Skardal et al., Sci. Rep. 7, 8837 (2017). Copyright 2017 Authors, licensed under a Creative Commons Attribution (CC BY) license.88 (b) (i) Schematic of the pumpless microfluidic system hosting cardiac and liver co-culture and the interface used to measure functionality (cardiomyocytes on cantilevers and on MEA chips); (ii) heart–liver co-culture and cardiac response upon cyclophosphamide treatment (9 mM) in presence and absence of hepatocytes. All values are normalized to the control before drug administration (a p <0.08, *p <0.05, ***p <0.001); (iii) heart–liver co-culture and cardiac response upon terfenadine treatment (10 μM) in presence and absence of hepatocytes. All values are normalized to the control before drug administration (a p <0.08, *p <0.05, **p <0.01). Reprinted with permission from Oleaga et al., Biomaterials 182, 176–190 (2018). Copyright 2018 Elsevier.91 (c) (i) Exploded view of the liver–heart organoids-on-chip system: top layer, through-hole PDMS layer, polycarbonate porous membrane and bottom layer. Assessment of clomipramine-induced cardiotoxicity (1 μM clomipramine for 24 and 48 h) after liver metabolism on the liver–heart organoids-on-chip: (ii) cell viability and (iii) beating rate of cardiac tissues with and without liver organoids. N = 3, mean ± SD (*P <0.05, **P <0.01, ***P <0.001); (iv) beating motion track of cardiac organoids with different drug treatments and the quantification of mean beating velocity of each condition (N = 3, mean ± SD; *P <0.05, **P <0.01, ***P <0.001). Republished with permission from Yin et al., Lab Chip 21, 571–581 (2021). Copyright 2021 Clearance Center, Inc.95
FIG. 3. (a) (i) Concept of the modular multitissue chip hardware system setup for culture of three different models connected via a central fluid routing breadboard; (ii) illustration of the two drug, two organoid interactions; (iii) cardiac organoids beating values in response to both 0.1 μM propranolol and 0.5 μM epinephrine with presence and absence of the liver module; (iv) increases in beating from epinephrine addition are blocked by 0.1 μM propranolol in the absence or presence of liver module (both organoids or 2D hepatocytes). 2D hepatocytes metabolism is reduced in comparison to hepatic organoids. Statistical significance: *p <0.05. Reproduced with permission from Skardal et al., Sci. Rep. 7, 8837 (2017). Copyright 2017 Authors, licensed under a Creative Commons Attribution (CC BY) license.88 (b) (i) Schematic of the pumpless microfluidic system hosting cardiac and liver co-culture and the interface used to measure functionality (cardiomyocytes on cantilevers and on MEA chips); (ii) heart–liver co-culture and cardiac response upon cyclophosphamide treatment (9 mM) in presence and absence of hepatocytes. All values are normalized to the control before drug administration (a p <0.08, *p <0.05, ***p <0.001); (iii) heart–liver co-culture and cardiac response upon terfenadine treatment (10 μM) in presence and absence of hepatocytes. All values are normalized to the control before drug administration (a p <0.08, *p <0.05, **p <0.01). Reprinted with permission from Oleaga et al., Biomaterials 182, 176–190 (2018). Copyright 2018 Elsevier.91 (c) (i) Exploded view of the liver–heart organoids-on-chip system: top layer, through-hole PDMS layer, polycarbonate porous membrane and bottom layer. Assessment of clomipramine-induced cardiotoxicity (1 μM clomipramine for 24 and 48 h) after liver metabolism on the liver–heart organoids-on-chip: (ii) cell viability and (iii) beating rate of cardiac tissues with and without liver organoids. N = 3, mean ± SD (*P <0.05, **P <0.01, ***P <0.001); (iv) beating motion track of cardiac organoids with different drug treatments and the quantification of mean beating velocity of each condition (N = 3, mean ± SD; *P <0.05, **P <0.01, ***P <0.001). Republished with permission from Yin et al., Lab Chip 21, 571–581 (2021). Copyright 2021 Clearance Center, Inc.95CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. D. J. Meyer, “ The Liver,” in Canine Feline Cytology (Elsevier, 2010), Vol. 27, pp. 226– 248.
  2. 2016, Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs, Sci. Rep., 6, 20030, 10.1002/adfm.201805792 · DOI · Paper page
  3. D. Lowe, “ The latest on drug failure and approval rates,” Sci. Transl. Med. 2, 14ps2 (2019).

Cited by

See all 53

Metadata

Authors
Ferrari, E., & Rasponi, M.
Affiliations
Politecnico di Milano (IT)
Corresponding author
Rasponi, Marco
Venue
APL Bioengineering
Published
2021-07-14
Volume
5
Issue
3
Pages
031505-031505
ISSN
2473-2877 (ISSN-L)
OpenAlex
W3180743733
Cited by
53
References
116
Citations by year
2026: 14 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 6 · 2021: 1
FWCI
0.70
Type
journal article
Language
en
Open access
Licence
Locations
  • APL Bioengineering (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Virtual Community of Pathological Anatomy (University of Castilla La Mancha) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Italian Ministry of Health (GR-2016-02364990)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
organ-on-a-chip, liver-on-a-chip, drug safety testing, drug toxicity, drug metabolism, off-target toxicity, drug development, in vitro model, drug attrition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.